Cirrhosis, the end-stage of liver progressive fibrosis, is the 11th leading cause of mortality and 15th leading cause of morbidity in the world. Non-alcoholic steatohepatitis (NASH) is a significant risk factor for the development of cirrhosis.
NASH - Methodology
Species: mice
Amylin liver NASH (AMLN) diet or high-fat/choline deficient (HFCD) diet
This model proves to be an excellent option for evaluating the effectiveness of novel drug compounds, especially those that modify pathways associated with steatohepatitis and fibrosis.
